Eden Pharmaceutical Limited - Accounts to registrar (filleted) - small 18.2

REGISTERED NUMBER: 04609974 (England and Wales)

Financial Statements for the Year Ended 30 September 2021

for

Eden Pharmaceutical Limited

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTORS:

N Thakrar

S Thakrar

Ms S Thakrar

SECRETARY:

Mrs M Thakrar

REGISTERED OFFICE:

Unit 4 Stonefield Way

Ruislip

Middlesex

HA4 0JW

REGISTERED NUMBER:

04609974 (England and Wales)

ACCOUNTANTS:

CAAT Advisory Ltd

Wework Southbank Central

30 Stamford Street

London

SE1 9PY

FIXED ASSETS

Investment property

4

17,583,998

17,583,998

CURRENT ASSETS

Debtors

5

1,725,669

2,388,722

Cash at bank

1,628

183

1,727,297

2,388,905

CREDITORS

Amounts falling due within one year

6

6,044,795

7,807,941

NET CURRENT LIABILITIES

(4,317,498

)

(5,419,036

)

TOTAL ASSETS LESS CURRENT LIABILITIES

13,266,500

12,164,962

CAPITAL AND RESERVES

Called up share capital

8

200

200

Retained earnings

13,266,300

12,164,762

SHAREHOLDERS' FUNDS

13,266,500

12,164,962

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2021 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 30 June 2022 and were signed on its behalf by:

N Thakrar - Director

1.	STATUTORY INFORMATION

Eden Pharmaceutical Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Investment property

Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2020 - 3 ) .

4.	INVESTMENT PROPERTY

Total

£

FAIR VALUE

At 1 October 2020

and 30 September 2021

17,583,998

NET BOOK VALUE

At 30 September 2021

17,583,998

At 30 September 2020

17,583,998

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

30.9.21

30.9.20

£

£

Other debtors

1,725,669

2,388,722

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

30.9.21

30.9.20

£

£

Taxation and social security

215,505

676,841

Other creditors

5,829,290

7,131,100

6,044,795

7,807,941

7.	SECURED DEBTS

In 2018 bank borrowings secured against the company's assets was replaced by borrowings from a related company Twilight Real Estate Limited, where all related company bank borrowings were consolidated into one bank loan.

8.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

30.9.21

30.9.20

value:

£

£

200

Ordinary

1

200

200

9.	RELATED PARTY DISCLOSURES

10.	ULTIMATE CONTROLLING PARTY